Progress on RNAi-based molecular medicines
- PMID: 22915846
- PMCID: PMC3418169
- DOI: 10.2147/IJN.S31897
Progress on RNAi-based molecular medicines
Abstract
RNA interference (RNAi) is a promising strategy to suppress the expression of disease-relevant genes and induce post-transcriptional gene silencing. Their simplicity and stability endow RNAi with great advantages in molecular medicine. Several RNAi-based drugs are in various stages of clinical investigation. This review summarizes the ongoing research endeavors on RNAi in molecular medicine, delivery systems for RNAi-based drugs, and a compendium of RNAi drugs in different stages of clinical development. Of special interest are RNAi-based drug target discovery and validation, delivery systems for RNAi-based drugs, such as nanoparticles, rabies virus protein-based vehicles, and bacteriophages for RNA packaging.
Keywords: RNA interference; delivery systems; liposome; molecular medicines; nanoparticle.
Figures

References
-
- Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811. - PubMed
-
- Hannon GJ. RNA interference. Nature. 2002;418(6894):244–251. - PubMed
-
- Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004;431(7006):343–349. - PubMed
-
- Novina CD, Sharp PA. The RNAi revolution. Nature. 2004;430(6996):161–164. - PubMed
-
- Pushparaj PN, Aarthi JJ, Manikandan J, Kumar SD. siRNA, miRNA, and shRNA: in vivo applications. J Dent Res. 2008;87(11):992–1003. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources